MAIA Biotechnology Files 8-K

Ticker: MAIA · Form: 8-K · Filed: Oct 23, 2025 · CIK: 1878313

Sentiment: neutral

Topics: 8-K, disclosure, financials

TL;DR

MAIA Bio filed an 8-K on Oct 23 for events on Oct 19, covering Reg FD, other events, and financials.

AI Summary

MAIA Biotechnology, Inc. filed an 8-K on October 23, 2025, reporting events that occurred on October 19, 2025. The filing includes information related to Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The company is incorporated in Delaware and its principal executive offices are located in Chicago, IL.

Why It Matters

This 8-K filing provides updates on MAIA Biotechnology's corporate activities and financial reporting, which are important for investors to monitor the company's status.

Risk Assessment

Risk Level: low — This filing is a routine 8-K report and does not appear to contain significant new risks or material adverse information.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

This 8-K filing serves to report on Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits for MAIA Biotechnology, Inc.

When was the earliest event reported in this filing?

The earliest event reported in this filing occurred on October 19, 2025.

On what date was this 8-K report filed with the SEC?

This 8-K report was filed with the SEC on October 23, 2025.

In which state is MAIA Biotechnology, Inc. incorporated?

MAIA Biotechnology, Inc. is incorporated in Delaware (DE).

What is the business address of MAIA Biotechnology, Inc.?

The business address of MAIA Biotechnology, Inc. is 444 West Lake Street, Suite 1700, Chicago, IL 60606.

Filing Stats: 731 words · 3 min read · ~2 pages · Grade level 11 · Accepted 2025-10-23 09:15:34

Filing Documents

01 Other Events

Item 8.01 Other Events 1. The Company has prepared a poster (the "Poster") entitled "Presentation 1: A Phase 2 Study of Ateganosine (THIO; 6-thio-2'-deoxyguanosine) in Combination with Immune Checkpoint Inhibitor (ICI) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Resistant to Prior ICI and Chemotherapy: THIO-101 Trial ("THIO-101 Trial Poster"). The THIO-101 Poster was presented at the European Society for Medical Oncology (ESMO) Congress 2025 held in Berlin, Germany starting on October 19, 2025 and posted to the Company's website on such date, a copy of which is filed as Exhibit 99.2 to this Report and is hereby incorporated by reference. 2. The Company has prepared a poster (the "Poster") entitled Presentation 2: A Phase 3 Study of Ateganosine (THIO) Sequenced with Immune Checkpoint Inhibitor (ICI) versus Standard of Care Chemotherapy in ICI-Resistant Advanced NSCLC: THIO-104 Trial in Progress ("THIO-104Trial Poster"). The THIO-104 Poster was presented ESMO starting on October 19, 2025 and posted to the Company's website on such date, a copy of which is filed as Exhibit 99.3 to this Report and is hereby incorporated by reference. Each of the THIO-101 Trial Poster and THIO-104 Trial Poster contain forward-looking statements, and as a result, investors should not place undue reliance on these forward-looking statements. Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated October 23, 2025 99.2 THIO-101 Trial Poster 99.3 THIO-104 Trial Poster 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 23, 2025 MAIA BIOTECHNOLOGY, INC. By: /s/ Vlad Vitoc Name: Vlad Vitoc Title: Chief Executive Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing